Leadership Changes at STERIS
In a significant announcement, STERIS plc (NYSE: STE) shared that long-time Chief Financial Officer (CFO) Michael J. Tokich will be succeeded by Karen L. Burton, currently the Chief Accounting Officer. This transition comes after Tokich's impressive 17-year tenure as CFO, during which he played a pivotal role in the company's growth and success.
Celebrating Michael J. Tokich's Contributions
Michael Tokich's journey with STERIS began in 2000 as Assistant Controller. Over the years, he climbed the ranks, showcasing remarkable leadership and financial acumen. Under his guidance, STERIS witnessed an impressive expansion, with revenue quadrupling and market capitalization skyrocketing from $1 billion to $22 billion. This robust growth is a testament to his dedication and strategic vision.
Growth Under Tokich's Leadership
During Tokich's leadership, STERIS has not only strengthened its financial standing but also diversified its operations. His responsibilities extended beyond traditional finance functions, encompassing regulatory compliance, IT, and government affairs. This multifaceted approach has positioned STERIS as a leader in infection prevention products and services, ensuring that patient care remains at the forefront of their mission.
Introducing Karen L. Burton as the New CFO
Taking over from Tokich, Karen L. Burton has been part of the STERIS family since 2004, starting as Assistant Controller before advancing to Chief Accounting Officer in 2017. Her extensive experience within the company equips her well for this new role, where she will oversee all global finance functions and IT. The collaboration between Tokich and Burton over the last two decades has laid a strong foundation for a smooth transition.
Building on a Legacy
As Burton steps into her new role, there is a palpable sense of continuity and stability within STERIS. According to CEO Dan Carestio, the transition has been meticulously planned, a credit to both Tokich and Burton. Their shared history and mutual respect promise to ensure that STERIS will continue to thrive and evolve under new leadership.
About STERIS
STERIS is a prominent global provider of innovative products and services that enhance patient care with a strong emphasis on infection prevention. Their commitment to health and safety positions them as a trusted partner in healthcare and life sciences. By continuously innovating and adapting to the needs of customers, STERIS aims to create a healthier world.
Looking Ahead with Confidence
The leadership change at STERIS reflects not only a new chapter for the company but also a testament to its solid foundations built by dedicated leaders. As Karen L. Burton takes on her new responsibilities, she is expected to carry forward the mission of STERIS, focusing on innovation, quality, and patient safety.
Frequently Asked Questions
Who is the new CFO of STERIS?
Karen L. Burton has been appointed as the new Chief Financial Officer of STERIS, succeeding Michael J. Tokich.
What were Michael J. Tokich's contributions to STERIS?
Tokich played a vital role in STERIS's growth, with revenue quadrupling and significant increases in market capitalization during his tenure.
How long did Tokich serve as CFO?
Michael J. Tokich served as CFO for 17 years, beginning his career at STERIS in 2000.
What is Karen L. Burton's background?
Burton has been with STERIS for nearly two decades, starting as Assistant Controller and most recently serving as Chief Accounting Officer.
What is the mission of STERIS?
STERIS is dedicated to supporting patient care with a strong focus on infection prevention and health safety, offering innovative products and services globally.
